

Research

Open Access

## Differential susceptibility of C57BL/6NCr and B6.Cg-Ptprc<sup>a</sup> mice to commensal bacteria after whole body irradiation in translational bone marrow transplant studies

Raimon Duran-Struuck\*<sup>1,2</sup>, Adam Hartigan<sup>2</sup>, Shawn G Clouthier<sup>2</sup>, Melissa C Dyson<sup>1</sup>, Kathi Lowler<sup>2</sup>, Erin Gatza<sup>2</sup>, Isao Tawara<sup>2</sup>, Tomomi Toubai<sup>2</sup>, Elisabeth Weisiger<sup>2</sup>, Kelly Hugunin<sup>1</sup>, Pavan Reddy<sup>2</sup> and John E Wilkinson<sup>1</sup>

Address: <sup>1</sup>Unit for Laboratory Animal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA and <sup>2</sup>Department of Internal Medicine, Bone Marrow Transplant Section, University of Michigan Medical School, Ann Arbor, MI, USA

Email: Raimon Duran-Struuck\* - [raimon.duran-struuck@tbrc.mgh.harvard.edu](mailto:raimon.duran-struuck@tbrc.mgh.harvard.edu); Adam Hartigan - [ajhart@umich.edu](mailto:ajhart@umich.edu); Shawn G Clouthier - [clouthie@umich.edu](mailto:clouthie@umich.edu); Melissa C Dyson - [mcdyson@umich.edu](mailto:mcdyson@umich.edu); Kathi Lowler - [kpl@umich.edu](mailto:kpl@umich.edu); Erin Gatza - [egatza@umich.edu](mailto:egatza@umich.edu); Isao Tawara - [itawara@umich.edu](mailto:itawara@umich.edu); Tomomi Toubai - [tomomit@umich.edu](mailto:tomomit@umich.edu); Elisabeth Weisiger - [eweisige@med.umich.edu](mailto:eweisige@med.umich.edu); Kelly Hugunin - [kellyhug@med.umich.edu](mailto:kellyhug@med.umich.edu); Pavan Reddy - [reddypr@umich.edu](mailto:reddypr@umich.edu); John E Wilkinson - [jerby@umich.edu](mailto:jerby@umich.edu)

\* Corresponding author

Published: 28 February 2008

Received: 9 October 2007

*Journal of Translational Medicine* 2008, **6**:10 doi:10.1186/1479-5876-6-10

Accepted: 28 February 2008

This article is available from: <http://www.translational-medicine.com/content/6/1/10>

© 2008 Duran-Struuck et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

### Abstract

**Background:** The mouse is an important and widely utilized animal model for bone marrow transplant (BMT) translational studies. Here, we document the course of an unexpected increase in mortality of congenic mice that underwent BMT.

**Methods:** Thirty five BMTs were analyzed for survival differences utilizing the Log Rank test. Affected animals were evaluated by physical examination, necropsy, histopathology, serology for antibodies to infectious disease, and bacterial cultures.

**Results:** Severe bacteremia was identified as the main cause of death. Gastrointestinal (GI) damage was observed in histopathology. The bacteremia was most likely caused by the translocation of bacteria from the GI tract and immunosuppression caused by the myeloablative irradiation. Variability in groups of animals affected was caused by increased levels of gamma and X-ray radiation and the differing sensitivity of the two nearly genetically identical mouse strains used in the studies.

**Conclusion:** Our retrospective analysis of thirty five murine BMTs performed in three different laboratories, identified C57BL/6NCr (Ly5.1) as being more radiation sensitive than B6.Cg-Ptprc<sup>a</sup>/NCr (Ly5.2). This is the first report documenting a measurable difference in radiation sensitivity and its effects between an inbred strain of mice and its congenic counterpart eventually succumbing to sepsis after BMT.

## 1. Introduction

Bone marrow transplantation (BMT) is a common therapy for many neoplastic and non-neoplastic conditions [1]. Current research is focused on the development of more efficient transplant regimens and therapies [1]. Before receiving a donor bone marrow (BM) graft, BMT patients undergo preparatory regimens (which often include irradiation) to deplete the host BM. Complications of BMT include viral, bacterial or fungal infections secondary to bone marrow ablation, and relapse of neoplastic disease [2,3]. Few human patients die directly from the preparatory regimens (chemotherapy, radiation) because of the availability of supportive care. However, debilitated high risk transplant patients require careful titration of the myeloablative therapy to prevent multiorgan disease [4,5]. Some of these complications are related to failure of engraftment. One of the most deleterious side effects of allogeneic BMT (when donor and recipient are genetically different) is graft-versus-host disease (GVHD) [6]. Grafted donor cells recognize the host (recipient of BMT) tissues as foreign leading to GVHD. Acute GVHD is defined as a disease appearing within 100 days post-BMT which targets the skin, liver, lung, thymus and secondary lymphoid tissues [7].

The mouse is one of the most utilized animal models for translational BMT studies. With the development of inbred strains of mice, many discoveries in the field of immunology, immunogenetics, and radiation oncology have taken place [8]. Inbred strains of mice permit the study of BMT in genetically identical and genetically variable systems. Transplantation between animals within the same strain allow for modeling of autotransplants or transplants between genetically identical twins (syngeneic). Genetically different donor and recipient strains allow modeling of transplantation between genetically different individuals (allogeneic). The mice in this report came from a number of BMT studies conducted by three laboratories where they utilize inbred strains for both syngeneic and allogeneic BMTs. There are three groups of BMT recipient per experiment: 1) syngeneic bone marrow recipients (syngenic BMTs) in which all animals are expected to survive. 2) allogeneic bone marrow recipients (allogenic BMTs) in which animals are expected to eventually succumb to GVHD, and 3) experimental allogeneic transplant recipients (experimental transplants) which receive allogeneic bone marrow with genetically induced modifications or treatments thought to prevent or decrease GVHD. Experimental animals are expected to have improved survival compared to the allogeneic control groups.

In general, mice irradiated for BMT studies experience lethargy and malaise of one week duration due to radiation induced multisystem organ damage. Commonly, all

animals, whether syngeneic or allogeneic survive the post-irradiation period. Syngeneic animals usually recover within two weeks, while allogeneic groups experience a biphasic illness. After the first week of irradiation sickness, allogeneic recipients undergo a relatively short recovery period prior to becoming sick for the second time due to GVHD. Animals developing GVHD, die as early as 12–14 days post-BMT and as late as 30–40 days post-BMT depending on the degree of genetic mismatch. Mice developing GVHD may exhibit diarrhea, skin lesions (ulcerations) and overall lethargy and anorexia as a consequence of the damage to the classical GVHD target organs (skin, gastrointestinal tract, liver, thymus) [9] similar to man.

In our studies, we observed an unexpected increase in mortality very early after transplantation. One of the most striking findings was facial swelling in the affected animals. Premature deaths in experimental murine models of BMT cause significant complications in interpretation of the experimental results and delay it's translation to the clinic. Furthermore, it greatly increases expense due to the necessity of using large numbers of mice, as well as the effort of the investigators. These economic factors, the impact on experiment outcomes, and the humane considerations all indicate the need to minimize premature deaths and better understand the limitations of the animal models utilized for human research. In our studies because of the difference in the non-GVHD related early mouse deaths in both syngeneic and allogeneic BMTs, we carefully evaluated the environmental, genetic, treatment, and pathologic factors associated with early death in a large group of BM transplanted mice.

## 2. Materials and methods

### 2.1 Mice

The strains of mice used as recipients in the discussed BMT studies were; C57BL/6NCr referred to as Ly5.1 and B6.Cg-Ptprc<sup>a</sup>/NCr, commercially available as B6-LY5.2/Cr, and referred throughout this manuscript as Ly5.2. The specific background strain from which the Ly5.2 gene comes from is unknown. There has been considerable confusion concerning the correct nomenclature for alleles of the protein-tyrosine phosphatase, receptor type c locus (Ptprc), formerly Ly5. Ly5.1 and Ly5.2 nomenclature is still commonly utilized in transplantation. The nomenclature used in this manuscript is consistent with The Jackson Laboratory (Jax) mouse genome informatics and Charles River Laboratories. Animals were housed in AAALAC accredited specific pathogen free rodent facilities at the University of Michigan in non-sterilized, ventilated racks and supplied with commercial rodent food. Animals received tap water from municipal sources until bone marrow transplantation at which time they received acidified water, pH of 2.9–3.1 for 21 days. All animals were negative for all pathogens included in the assessment profile (Charles River®)

and tested at the vendor's facility prior to shipping. These included: Ectromelia, Enzootic Diarrhea of Infant Mice, Mouse Hepatitis Virus, Mouse Parvovirus, Minute Mouse Virus, Reovirus-3, Sendai virus, Theiler's Murine Encephalomyelitis Virus, Lymphocytic Choriomeningitis virus, Adenovirus, *Mycoplasma pulmonis*, Polyoma virus, Pneumonia virus of mice, Cilia-associated Respiratory Bacillus. Animals received from the National Cancer Institute (NCI) were also negative for all bacterial, viral and protozoal diseases mentioned above and documented in their surveillance reports.

All procedures were approved by the University of Michigan's Animal Care and Use Committee.

### 2.2 Irradiation and BMT

Prior to transplantation, all animals received a myeloablative radiation (from 800–1300 cGy) given in a single dose, or split into two doses 3–4 hours apart as described previously [10,11]. The laboratories used the gamma irradiator, Gammacell 40<sup>®</sup> (+/- 0.8 rad/min) MDS Nordion, Inc. (Ontario, Canada) or an X-ray electrovoltage instrument (Philips 250 kV orthovoltage unit, 4 rad/min). All animals were placed in a Raddisk<sup>®</sup> (Braintree Scientific, Braintree, MA) when irradiated in the Gammacell 40. When exposed to X-rays animals were maintained in a custom made ventilated Plexiglas restraining device. The donor bone marrow recipients' immune system was reconstituted intravenously via the tail vein with  $5 \times 10^6$  bone marrow cells with or without isolated splenic T cells ( $5 \times 10^5$  to  $5 \times 10^6$  cells), total splenocytes or tumor cells given on the same day of irradiation. BMTs were performed in dedicated procedure rooms in the animal facilities (under HEPA-filtered hoods) or the laboratories (in a clean dedicated area for injection). The recipients were placed in a tail vein injector (custom made) and a maximum of 250  $\mu$ L of BM inoculum was delivered per animal. Transplanted animals were housed in separate rooms from untreated mice.

### 2.3 Pathology

Severely ill animals that were identified 4–10 days post-BMT in different experiments were humanely euthanized. Organs (brain, thoracic and abdominal organs) were harvested and placed in 10% formalin for 24 hours and then 70% ethanol prior to slide preparation. The tissues were cut at 5  $\mu$ m in thickness and stained with H&E prior to analysis.

### 2.4 Blood and tissue cultures

Animals were anesthetized and an intracardiac or orbital terminal phlebotomy was performed. Blood and tissue cultures of kidneys, liver, spleen, heart and lungs were aseptically obtained and routinely processed.

### 2.5 In-house serology

177 naïve mice used as recipients were assessed in-house (in addition to the health status reports from NCI and Charles River Laboratories) for evidence of 13 viruses and two bacteria using the Charles River Diagnostic Laboratories Assessment Profile (Charles River<sup>®</sup>) ELISA as described previously. Mice were from the same vendor and were analyzed during the same time period when premature deaths were occurring. The 177 mice analyzed (and chosen at random) belonged to the three investigators as they shared a common mouse arrival holding room.

### 2.8 Retrospective study of common factors

We evaluated factors related to: laboratory personnel, housing, BM inoculum differences, irradiation source (gamma or X-ray), irradiation dose, time of year BMTs were performed and housing location before and after transplantation.

### 2.8 Statistical analysis

Statistical analysis was performed as described [12]. The Wilcoxon rank test was used to analyze irradiation doses and survival.  $p < 0.05$  was considered statistically significant. The Cochran-Mantel-Haenszel statistic for general association was performed to compare season of year (winter, spring, summer) and laboratory personnel (between three laboratories).  $p < 0.05$  was considered statistically significant. Odds ratios with a 95% confidence interval was performed when comparing radiation source (X-ray or Gamma irradiator), animal holding rooms, or inoculum differences.  $p < 0.05$  considered statistically significant.


## 3. Results

### 3.1 Physical exam of affected recipients and early deaths post-BMT

On physical exam affected mice were lethargic, had a hunched posture and exhibited decreased mobility. The most striking clinical sign was pronounced facial swelling (Figure 1A). In some experiments as many as 100% of the syngeneic controls died within a week (Table 1). When an experiment was affected, 25–100% of the animals would exhibit the specific clinical sign of facial swelling (Table 1).

### 3.2 Systemic bacterial infection identified in affected animals on gross and histopathology analysis

Necropsy was performed on animals that exhibited facial swelling. Gross pathology revealed severe cervicothoracic swelling (Figure 1B) restricted to the dermis and subcutaneous layers. The salivary glands and the submandibular lymph nodes were often enlarged. Some cases exhibited severe swelling of the tongue.



### Figure 1

Gross examination showed marked facial and submandibular swelling (A). Histopathology of cervical (B) and mesenteric (C, D) lymph nodes showing acute, severe, necrotizing lymphadenitis and cellulitis with intralymphatic bacteria at 4× (B), 10× (C) and 20× (D) magnification. Acute severe necrosis (C) of mesenteric lymph node.

Histopathology identified an acute, severe, locally extensive, necrotizing cervical lymphadenitis and cellulitis with many intralymphatic bacteria (Figure 1B,C,D). There was also extensive necrosis in the liver (Figure 2B) and spleen. Numerous organs including the heart and liver contained abundant bacteria with no reaction (Figure 2A,B). Spleen, lymph nodes (Figure 1B,C,D), blood, and bone marrow (Figure 2C) were leukocyte deficient indicating a state of immunosuppression. The villi of the small intestine were severely blunted and fused consistent with radiation induced gastrointestinal damage (Figure 2D).

### 3.3 Commensal bacteria and their toxins identified in blood and tissues

In view of the above results, bacterial cultures were analyzed from twelve affected animals exhibiting the exact same symptoms from different experiments. These cultures revealed a mix of bacteria in both blood and tissues

including *Escherichia coli*, *Pseudomonas spp.*, *Enterococci spp.*, *Staphylococcus spp.*, and *Streptococci spp.*

### 3.4 In-house serological analysis of naive animals

We aimed to rule out the possibility that naïve mice shipped from our vendors, and documented to be negative of all infectious diseases tested (described in materials and methods) did not become positive after being housed in our facilities. Therefore, 177 naïve animals (to be used in future transplants and which were housed in a common room shared by the three investigators) were tested a second time for the same pathogens utilizing the Charles River Diagnostic Laboratories Assessment Profile, (Charles River®) (refer to materials and methods). All animals were negative for all pathogens tested.

**Table 1: C57BL/6NCr are sensitive to irradiation doses >1000 cGy.**

Inoculum type	Recipients	First day Symptoms observed post BMT	#affected	% affected	Treatment	Rads (cGy)	Irradiator
BM+ Tc	B6 (Ly5.1)	6	2/4	50		1300 split	Xray
BM + splenocytes	B6 (Ly5.1)	7	2/4	50		1100 single	Xray
BM + Tc	B6 (Ly5.1)	9	2/4	50		1100 single	Xray
BM+Tc	B6 (Ly5.1)	7	1/3	33	EL-4	1100 single	Xray
BM+Tc	B6 (Ly5.1)	7	3/12	25	EL-4	1100 single	Xray
BM+T c	B6 (Ly5.1)	6	2/6	33	EL-4	1100 single	Xray
BM+Tc	B6 (Ly5.1)	6	8/8	100	EL-4	1100 single	Xray
BM+Tc	B6 (Ly5.1)	6	11/20	55		1100 single	gamma
BM+Tc	B6 (Ly5.1)	6	2/4	50		1100 single	gamma
BM+Tc	B6 (Ly5.1)	6	4/5	80		1100 split	gamma
BM+Tc	B6 (Ly5.1)	5	4/6	66		1300 split	gamma
BM+Tc	B6 (Ly5.1)	5	9/11	81	MBL-2	1300 split	gamma
BM+DC	B6 (Ly5.1)	4	5/5	100	DC	1100 single	X-ray
BM+Tc	B6 (Ly5.1)	5	5/5	100		1100 single	gamma
BM+Tc	B6 (Ly5.1)	5	3/9	33		1000 single	gamma

C57BL/6NCr underwent BMT and exhibited unexpected deaths. Animals were reconstituted with bone marrow (BM) and T-cells (Tc), or bulk splenocytes (splenocytes) or dendritic cells (DC). Symptoms started as early as day +4 post-transplantation. Some animals received MBL-2 or EL-4 leukemia cells. Ionizing radiation was given in a single or fractionated (split) dose or administered with an X-ray diffraction instrument. Split regimens were delivered in two equal amounts separated at least 3 hours apart.


### 3.5 Multi-factorial analysis of BM transplanted animals

We retrospectively evaluated environmental, experimental and animal factors associated with the study including: strain of mouse, housing location, experimental equipment, the degree of irradiation, type of irradiation (gamma or X-ray), time a year (winter, spring, summer), laboratory (comparing BMTs from the three laboratories), treatment (splenocytes or tumor cells). Factors that were not common among the three laboratories involved were cell preparations, procedure rooms, housing location of transplanted animals, cell culture media, and surgical instruments. The most important factor identified in the early deaths was the dose of radiation and the genetic background of the recipient mice. Affected mice were identified to be among the C57BL/6NCr (Ly5.1) group while B6.Cg-Ptprca/NCr (Ly5.2) congenics were minimally or not affected (Table 2). Statistically significant differences in survival were found using a Wilcoxon rank test between Ly5.1 and Ly5.2 animals that received irradiation (Figure 3A,B). Increased mortality ( $p < 0.001$ ) was observed in the Ly5.1 mice that received  $\geq 1100$  cGy (Figure 3A). The strain of the donor mice, the inclusion of T cells or splenocytes in the inoculum, and genetic compatibility of the donor and recipient did not affect morbidity and mortality. Radiation at, or under 1000 cGy in B6 Ly5.1 recipients had a significant ( $p < 0.001$ ) improvement in survival (Figure 3A and Table 3). When comparing variables for survival with more than two levels (laboratory and season), the test for general association for the different laboratories had a  $p = 0.165$  and seasonal influence had a  $p = 0.116$ . Odds ratios between differences by animal room post BMT had  $p$  value for the chi-

square statistic of 0.10. Odds ratios for being more affected with X-ray compared to gamma radiation had a  $p = 0.35$ . Odds ratio for groups that did not receive neither splenocytes nor tumor cells  $p = 0.62$ . We considered statistically significance if  $p < 0.05$ .

### 4. Discussion

In our studies we document the clear differences in mortality between C57BL/6NCr (Ly5.1) and B6.Cg-Ptprca/NCr (Ly5.2) C57BL/6Cr mice in BMT studies that utilized irradiation as the main immunosuppressive regimen for translational transplant studies. When syngenic animals (positive controls), which would otherwise survive, started dying, this made the transplants uninterpretable. The death of immunocompromised mice such as SCIDs and Nude (nu/nu) mice are common when exposed to bacterial, viral, parasitic or protozoal pathogens similar to immunocompromised individuals [13-17]. However following BMT, despite transient immunosuppression, immunocompetent transplanted animals usually survive for greater than seven days after the immunoablative treatment [10,18-23]. If there is lack of engraftment the animals will eventually succumb to infection secondary to BM aplasia [24,25] and anemia or thrombocytopenia. Premature death may occur if the BM inoculum is not successfully delivered, or the delivered cells are unable to engraft and repopulate the hemolymphatic system of the new host. In the cases reported here, all animals were given a BMT dose and were expected to survive the initial immunosuppressive period. Failure to deliver an appropriate dose of viable cells is unlikely because the intravenous tail vein injections were given by experienced



**Figure 2**  
 Histopathology of the heart (A), liver (B), bone marrow (C), and small intestine (D). Acute, severe bacterial myocarditis with intralésional bacteria (A) 10 $\times$ . Acute hepatic necrosis (arrow) (B) 20 $\times$ . Leukocyte deficient bone marrow (C) 10 $\times$ . Blunted villi (arrow) in small intestine (D) 10 $\times$ .


individuals and the Ly5.2 mice that were not affected were given the same dose, by the same route, and by the same personnel as those mice that died prematurely.

Animals might die early if aged, debilitated or if burdened by a subclinical infection that was not identified prior to myeloablation. This effect has also been observed in the clinic with elder or very critical patients [4]. In our studies, the mice undergoing transplantation were 3–8 months

**Table 2: Improved survival of B6.Cg-Ptprc<sup>a</sup>/NCr mice to radiation doses of 1000 and 1100 cGy.**

Inoculum type	Recip	Symptoms	#affected	% affected	Rads (cGy)	Irradiator
BM	B6 (Ly5.2)	None	0/10	0	1000 (single)	X-ray
BM	B6 (Ly5.2)	None	0/10	0	1000 (single)	X-ray
BM	B6 (Ly5.2)	None	0/10	0	1000 (single)	X-ray
BM+Tc	B6 (Ly5.2)	None	0/5	0	1100 (single)	gamma
BM+Tc	B6 (Ly5.2)	none	0/9	0	1100 (single)	gamma
BM+Tc	B6 (Ly5.2)	None	0/27	0	1100 (split)	gamma
BM +Tc	B6 (Ly5.2)	None	0/30	0	1100 (split)	gamma
BM+Tc	B6 (Ly5.2)	None	0/25	0	1100 (split)	gamma
BM+ Tc	B6 (Ly5.2)	Yes	7/24	29%	1100 single	gamma

B6.Cg-Ptprc<sup>a</sup>/NCr (B6LY5.2/Cr), referred as Ly5.2 congenics, receiving similar radiation doses as shown in Table I. Recipients were reconstituted in these experiments with either bone marrow (BM) alone or BM and T-cells (Tc).



**Figure 3**  
**B6 (Ly5.1) mice are more sensitive to irradiation than B6-Ly5.2.** (A) Survival comparison in the Ly5.1 mice after different irradiation doses. Ly5.1 are susceptible to irradiation doses  $\geq 1100$  cGy. All animals received a BMT the same day of irradiation (B). Survival comparison between congenic B6-Ly5.2 mice and Ly5.1 mice post irradiation doses of 1100 cGy, 1000 cGy or less. Ly5.2 mice are more radioresistant than Ly5.1 mice at TBI doses of 1100 cGy. \* $p < 0.001$ , \*\* $p = 0.068$ .

old and healthy (based on NCI's health reports). As previously mentioned, mice that receive myeloablative conditioning prior to BMT survive the time period immediately after the preparatory regimen (5–7 days post irradiation). By day +14 post-BMT, there is immunological recovery which is demonstrated by normal peripheral immune reconstitution [26]. As is expected in *in vivo* studies, some intra-animal variation may occur, however if a mortality over 20% in the syngeneic controls is observed, one must re-assess the experimental protocol. Mice receiving allogeneic BM, and T cells may die of severe GVHD after 2 weeks post-transplantation. Depending on the T cell and BM dose and the degree of mismatch, GVHD may develop before 14 days post-BMT. However, 1) syngeneic controls

should survive and 2) facial swelling should not be observed as it is not a feature of GVHD in mice.

The premature animal deaths in this study were independent of the transplant details (donor T cell source, personnel, housing, cell preparation, irradiation source, age and sex of recipient or housing facilities). Some mouse viruses have been documented to be immunosuppressive and impede stem cell differentiation [27-32] possibly having an influence in immune reconstitution and engraftment. Serology of 177 naïve animals to be used at a later time as either donor or recipients, were negative for all bacteria and viruses including parvoviruses. The strain of the recipient and the dose of irradiation were the two predominant

**Table 3: C57BL/6NCr survival at doses under 1000 cGy.**

Inoculum type	Recipients	Symptoms	#affected	% affected	Rads (cGy)	Irradiator
BM+Tc	B6 (Ly5.1)	None	0/5	0	1000 single	gamma
BM+Tc	B6 (Ly5.1)	None	0/5	0	800 split	X-ray
BM+Tc	B6 (Ly5.1)	None	0/5	0	800 split	gamma
BM+ Tc	B6 (Ly5.1)	None	0/5	0	900 single	gamma
BM+ Tc	B6 (Ly5.1)	None	0/6	0	900 single	gamma
BM+ Tc	B6 (Ly5.1)	None	0/5	0	900 single	gamma
BM+ Tc	B6 (Ly5.1)	None	0/3	0	900 single	gamma
BM+ Tc	B6 (Ly5.1)	None	0/6	0	1000 single	gamma
BM+ Tc	B6 (Ly5.1)	None	0/6	0	900 single	gamma
BM+ Tc	B6 (Ly5.1)	None	0/3	0	1000 single	gamma
BM+ Tc	B6 (Ly5.1)	None	0/5	0	1000 single	gamma

C57BL/6NCr that received  $\leq 1000$  cGy survived the bone marrow transplant.

factors influencing facial swelling and mortality in these BMT models (Figure 3A,B).

We identified *E. coli*, *Pseudomonas spp.*, *Enterococcus* and *Streptococci spp* in the blood and tissues. These pathogens have commonly been reported to affect immunocompromised animals [33]. In order to prevent infections in BMT mice some groups recommend treating the animals with antibiotics in the water in order to minimize bacterial contamination post irradiation. In our institution we utilize acidified (hyper-chlorinated) water with a pH = 2.9–3.0 [19,20] and have rarely experienced problems in mice in these study protocols.

Based on previous studies [22,23], gut damage in animals that are SPF (not germ free), have some degree of translocation of bacterial toxins (e.g. LPS) and possibly bacteria post-irradiation, which in turn causes a severe inflammatory response and severe hypotension. This is known to be mediated by TNF $\alpha$  and IL-1 inflammatory mediators [9]. However, and as previously mentioned, during uncomplicated bone marrow transplants, syngeneic animals recover successfully after this period. Based on the blood and tissue cultures and histopathology, we clearly document that the affected mice were severely septic. Even though death from sepsis may be expected in severely immunocompromised mice if challenged with a pathogen, early death from sepsis on transplanted animals, though possible, it is not common. In our studies, the systemic peri-BMT preparatory regimen caused a degree of damage where even syngeneic recipients were unable to successfully recover from the early post-transplant period. As documented, their deaths were likely caused by the translocation of gastrointestinal bacteria and their toxins into the circulation, and subsequently into other organ systems. Such effects continue to be an important co-morbidity factor in human BMTs [1].

Facial swelling has been documented in immunodeficient SCID mice after severe infections in their oropharyngeal regions [17,33]. Therefore, the swelling in our animals can, in part, be explained by the autoinoculation of bacteria during their vulnerable immunocompromised period as described in SCID mice.

In our studies the dose of radiation was one major factor in causing the premature deaths. It has been documented that splitting a single radiation dose into two equal half doses causes less GI damage [34]. Based on our retrospective study, we observed that only the animals that died at the early time points post-BMT (4–8 days) and exhibited facial swelling, were the mice that received the highest radiation doses performed in the laboratories (1100–1300 cGy). High radiation doses such as 1000 cGy have been documented to be relatively toxic when given to larger species such as dogs and man [35,36]. However, many strains and stocks of mice have historically been more resistant to irradiation (e.g. C3H strains) [37] while others are significantly more sensitive (e.g. BALB/c) [38] once again emphasizing the importance of genetics not only in BMT match/mismatches, but in the susceptibility to the preparatory regimens. These factors are also likely to impact human BMT outcomes.

In our retrospective analysis we have been able to identify that most of the animals affected have been C57BL/6NCr (Ly5.1) (Table 1 and Figure 3). B6.Cg-Ptprca/NCr (Ly5.2) syngeneic recipients receiving 1000–1100 cGy irradiation doses were less affected (Table 2 and Figure 3) by irradiation and the differences were statistically significant ( $p < 0.001$ ). This suggests that B6-Ly5.2 congenic mice are therefore more resistant to irradiation. One group of B6-Ly5.2 mice in Table 2 exhibited a 29% mortality. It is possible that 1100 cGy given in a single dose may be the radiation limit that Ly5.2 mice can withstand in our hands. We must mention that certain variability is always observed when performing *in vivo* experiments (even in



age matched and using inbred strains) and there can be unknown factors which may impact (hopefully to a lesser degree) the experimental outcomes. It is possible in the case of Ly5.2 animals mentioned above that human error calculating the irradiation dose may have influenced the outcome of this experiment, especially if we assumed that we are at the cusp of the maximal radiation dose tolerated by Ly5.2 mice. It has been our experience that Ly5.2 animals that received 1300 cGy as a single dose had a 90% mortality. In any case, and based on the number of animals included in this study, we show that Ly5.2 mice are more resistant to radiation and that no mortalities are observed when either splitting the 1100 radiation dose or decreasing the overall amount of radiation. There are a plethora of studies that have documented the link between the susceptibility of ionizing radiation and the genetic makeup [37-46] between different strains of mice and also man. For example DNA-protein kinases (DNA-Pks), which are important for DNA repair, were found to be diminished in BALB/c and 129/SvJ compared to C57BL/6 mice after being exposed to ionizing radiation [47]. In our specific study, we document for the first time a difference in sensitivity between two nearly genetically identical strains commonly used in biomedical research. Despite their nearly identical genetic makeup supported by immunological tolerance by the absence of GVHD [48] in allogeneic BMTs or rejection of skin grafts, there may still remain enough genetic disparity between the two strains to produce this observed difference in response to radiation. The mechanism of this differential sensitivity is unknown. It is possible that these two strains have differences in their DNA repair capabilities or radioprotective processes. It has been shown that the release of toxic nitric oxide radicals (NO<sub>r</sub>) can contribute to irradiation damage and that low NO<sub>r</sub> release post-irradiation is radioprotective [49]. It is also possible that Ly5.2 recipients may have decreased NO<sub>r</sub> release post irradiation compared to Ly5.1.

In conclusion, we have demonstrated for the first time a measurable difference in radiation sensitivity and its effects between two nearly genetically identical strains of mice commonly used for translational studies where C57BL/6N<sub>Cr</sub> die of bacteremia more readily than B6.Cg-Ptprc<sup>a</sup>/N<sub>Cr</sub> congenics at radiation doses over 1000 cGy.

### Abbreviations

Graft-versus-host disease (GVHD), C57BL/6N<sub>Cr</sub> (B6 Ly5.1 or Ly5.1), B6.Cg-Ptprc<sup>a</sup>/N<sub>Cr</sub> or B6-LY5.2/Cr (Ly5.2), total body irradiation (TBI)

### Authors' contributions

RDS wrote the manuscript, performed BMTs, and diagnosed all animal cases. AH performed BMTs, revised and designed manuscript and submitted pathology samples. SGC performed BMTs and participated in the design of

manuscript. IT participated in the design of manuscript and performed BMTs. TT, EG performed BMTs. EW, KL revised manuscript and participated in BMTs. KH performed statistics. MD edited the manuscript and provided serologic results. PR participated in the design of the manuscript and analyzed data. JEW performed all histopathology and diagnosis and participated in the design of the manuscript. All authors read and approved the manuscript.

### Funding

NIH/NCRR T32-RR07008-21A1 (R.D.S) and Unit for Laboratory Animal Medicine internal funds.

### Acknowledgements

We would like to acknowledge the help of Dr. Xuan Mai Vo and Dr. Mark Meyerhoff in reviewing the manuscript. Also we would like to thank all the husbandry and veterinary staff from the University of Michigan's Unit for Laboratory Animal Medicine.

### References

1. Copelan EA: **Hematopoietic Stem-Cell Transplantation.** *The New England Journal of Medicine* 2006, **354**:1813-1826.
2. Gratwohl A, Brand R, Frassonni F, Rocha V, Niederwieser D, Reusser P, Einsele H, Cordonnier C: **Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time.** *Bone marrow transplantation* 2005, **36**:757-769.
3. Yoo JH, Lee DG, Choi SM, Choi JH, Park YH, Kim YJ, Kim HJ, Lee S, Kim DW, Lee JW, Min WS, Shin WS, Kim CC: **Infectious complications and outcomes after allogeneic hematopoietic stem cell transplantation in Korea.** *Bone marrow transplantation* 2004, **34**:497-504.
4. Corradini P, Zallio F, Mariotti J, Farina L, Bregni M, Valagussa P, Ciceri F, Bacigalupo A, Doderio A, Lucesole M, Patriarca F, Rambaldi A, Scime R, Locasciulli A, Bandini G, Gianni AM, Tarella C, Olivieri A: **Effect of age and previous autologous transplantation on nonrelapse mortality and survival in patients treated with reduced-intensity conditioning and allografting for advanced hematologic malignancies.** *J Clin Oncol* 2005, **23**:6690-6698.
5. Valcarcel D, Martino R, Sureda A, Canals C, Altes A, Briones J, Sanz MA, Parody R, Constans M, Vilella SL, Brunet S, Sierra J: **Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies.** *European journal of haematology* 2005, **74**:144-151.
6. Ferrara JL, Deeg HJ: **Graft-versus-host disease.** *The New England journal of medicine* 1991, **324**:667-674.
7. Welniak LA, Blazar BR, Murphy WJ: **Immunobiology of allogeneic hematopoietic stem cell transplantation.** *Annual review of immunology* 2007, **25**:139-170.
8. Donnell Thomas ERS: **The Development of the Scientific Foundation of Hematopoietic Cell Transplantation Based on Animal and Human Studies.** In *Hematopoietic Cell Transplantation*. Edited by: KGB E Donnell Thomas, Stephen J Fohrman. Blackwell Science, Inc, Oxford, England; 1998:1-11.
9. Ferrara JL, Reddy P: **Pathophysiology of graft-versus-host disease.** *Seminars in hematology* 2006, **43**:3-10.
10. Teshima T, Reddy P, Liu C, Williams D, Cooke KR, Ferrara JL: **Impaired thymic negative selection causes autoimmune graft-versus-host disease.** *Blood* 2003, **102**:429-435.
11. Reddy P, Maeda Y, Liu C, Krijanovski OI, Korngold R, Ferrara JL: **A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses.** *Nature medicine* 2005, **11**:1244-1249.
12. Maeda Y, Levy RB, Reddy P, Liu C, Clouthier SG, Teshima T, Ferrara JL: **Both perforin and Fas ligand are required for the regula-**

- tion of alloreactive CD8+ T cells during acute graft-versus-host disease. *Blood* 2005, **105**:2023-2027.
13. McBride DF, Stark DM, Walberg JA: **An outbreak of staphylococcal furunculosis in nude mice.** *Laboratory animal science* 1981, **31**:270-272.
  14. Mayeux P, Dupepe L, Dunn K, Balsamo J, Domer J: **Massive fungal contamination in animal care facilities traced to bedding supply.** *Appl Environ Microbiol* 1995, **61**(6):2297-2301.
  15. Livingston RS, Franklin CL, Besch-Williford CL, Hook RR Jr, Riley LK: **A novel presentation of Clostridium piliforme infection (Tyzzer's disease) in nude mice.** *Laboratory animal science* 1996, **46**:21-25.
  16. Franklin CL, Riley LK, Livingston RS, Beckwith CS, Hook RR Jr, Besch-Williford CL, Hunziker R, Gorelick PL: **Enteric lesions in SCID mice infected with "Helicobacter typhlonicus," a novel urease-negative Helicobacter species.** *Laboratory animal science* 1999, **49**:496-505.
  17. Dietrich HM, Khaschabi D, Albin B: **Isolation of Enterococcus durans and Pseudomonas aeruginosa in a scid mouse colony.** *Laboratory animals* 1996, **30**:102-107.
  18. Cooke KR, Kobzik L, Martin TR, Brewer J, Delmonte J Jr, Crawford JM, Ferrara JL: **An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin.** *Blood* 1996, **88**:3230-3239.
  19. Reddy P, Ferrara JL: **Role of interleukin-18 in acute graft-vs-host disease.** *The Journal of laboratory and clinical medicine* 2003, **141**:365-371.
  20. Reddy P, Maeda Y, Hotary K, Liu C, Reznikov LL, Dinarello CA, Ferrara JL: **Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect.** *Proceedings of the National Academy of Sciences of the United States of America* 2004, **101**:3921-3926.
  21. Teshima T, Ordemann R, Reddy P, Gagrin S, Liu C, Cooke KR, Ferrara JL: **Acute graft-versus-host disease does not require alloantigen expression on host epithelium.** *Nature medicine* 2002, **8**:575-581.
  22. Cooke KR, Hill GR, Crawford JM, Bungard D, Brinson YS, Delmonte J Jr, Ferrara JL: **Tumor necrosis factor-alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease.** *The Journal of clinical investigation* 1998, **102**:1882-1891.
  23. Cooke KR, Olkiewicz K, Erickson N, Ferrara JL: **The role of endotoxin and the innate immune response in the pathophysiology of acute graft versus host disease.** *Journal of endotoxin research* 2002, **8**:441-448.
  24. Ganesh C, Jagetia, N.G.G.P.V.N.R.M.S.B. **Evaluation of the radioprotective effect of Liv 52 in mice.** 2006:490-502.
  25. Jagetia GC, Baliga MS: **Polyherbal extract of septilin protects mice against whole body lethal dose of gamma radiation.** *Phytother Res* 2004, **18**:619-623.
  26. Ojilelo CI, Cooke K, Mancuso P, Standiford TJ, Olkiewicz KM, Clouthier S, Corrion L, Ballinger MN, Toews GB, Paine R 3rd, Moore BB: **Defective phagocytosis and clearance of Pseudomonas aeruginosa in the lung following bone marrow transplantation.** *J Immunol* 2003, **171**:4416-4424.
  27. McKisic MD, Macy JD Jr, Delano ML, Jacoby RO, Paturzo FX, Smith AL: **Mouse parvovirus infection potentiates allogeneic skin graft rejection and induces syngeneic graft rejection.** *Transplantation* 1998, **65**:1436-1446.
  28. McKisic MD, Paturzo FX, Smith AL: **Mouse parvovirus infection potentiates rejection of tumor allografts and modulates T cell effector functions.** *Transplantation* 1996, **61**:292-299.
  29. Segovia JC, Bueren JA, Almendral JM: **Myeloid depression follows infection of susceptible newborn mice with the parvovirus minute virus of mice (strain i).** *Journal of virology* 1995, **69**:3229-3232.
  30. Segovia JC, Gallego JM, Bueren JA, Almendral JM: **Severe leukopenia and dysregulated erythropoiesis in SCID mice persistently infected with the parvovirus minute virus of mice.** *Journal of virology* 1999, **73**:1774-1784.
  31. Segovia JC, Guenechea G, Gallego JM, Almendral JM, Bueren JA: **Parvovirus infection suppresses long-term repopulating hematopoietic stem cells.** *Journal of virology* 2003, **77**:8495-8503.
  32. Segovia JC, Real A, Bueren JA, Almendral JM: **In vitro myelosuppressive effects of the parvovirus minute virus of mice (MVMi) on hematopoietic stem and committed progenitor cells.** *Blood* 1991, **77**:980-988.
  33. Brownstein DG: **Pathogenesis of bacteremia due to Pseudomonas aeruginosa in cyclophosphamide-treated mice and potentiation of virulence of endogenous streptococci.** *The Journal of infectious diseases* 1978, **137**:795-801.
  34. Valdes Olmos RA, Hoefnagel CA, van der Schoot JB: **Nuclear medicine in the monitoring of organ function and the detection of injury related to cancer therapy.** *European journal of nuclear medicine* 1993, **20**:515-546.
  35. Deeg HJ, Storb R, Longton G, Graham TC, Shulman HM, Appelbaum F, Thomas ED: **Single dose or fractionated total body irradiation and autologous marrow transplantation in dogs: effects of exposure rate, fraction size, and fractionation interval on acute and delayed toxicity.** *International journal of radiation oncology, biology, physics* 1988, **15**:647-653.
  36. Storb R, Raff RF, Graham T, Appelbaum FR, Deeg HJ, Schuening FG, Sale G, Seidel K: **Dose rate-dependent marrow toxicity of TBI in dogs and marrow sparing effect at high dose rate by dose fractionation.** *Biol Blood Marrow Transplant* 1999, **5**:155-161.
  37. Weil MM, Stephens LC, Amos CI, Ruifrok AC, Mason KA: **Strain difference in jejunal crypt cell susceptibility to radiation-induced apoptosis.** *International journal of radiation biology* 1996, **70**:579-585.
  38. Hanson WR, Fry RJ, Sallase AR, Frischer H, Ahmad T, Ainsworth EJ: **Comparison of intestine and bone marrow radiosensitivity of the BALB/c and the C57BL/6 mouse strains and their B6CF1 offspring.** *Radiation research* 1987, **110**:340-352.
  39. Iwakawa M, Noda S, Ohta T, Ohira C, Lee R, Goto M, Wkabayashi M, Matsui Y, Harada Y, Imai T: **Different radiation susceptibility among five strains of mice detected by a skin reaction.** *Journal of radiation research* 2003, **44**:7-13.
  40. Kallman RF: **The effect of dose rate on mode of acute radiation death of C57BL and BALB/c mice.** *Radiation research* 1962, **16**:796-810.
  41. Noda S, Iwakawa M, Ohta T, Iwata M, Yang M, Goto M, Tanaka H, Harada Y, Imai T: **Inter-strain variance in late phase of erythematous reaction or leg contracture after local irradiation among three strains of mice.** *Cancer detection and prevention* 2005, **29**:376-382.
  42. Ohta T, Iwakawa M, Oohira C, Noda S, Minfu Y, Goto M, Tanaka H, Harada Y, Imai T: **Fractionated irradiation augments inter-strain variation of skin reactions among three strains of mice.** *Journal of radiation research* 2004, **45**:515-519.
  43. Weil MM, Xia C, Xia X, Gu X, Amos CI, Mason KA: **A chromosome 15 quantitative trait locus controls levels of radiation-induced jejunal crypt cell apoptosis in mice.** *Genomics* 2001, **72**:73-77.
  44. Suga T, Ishikawa A, Kohda M, Otsuka Y, Yamada S, Yamamoto N, Shibamoto Y, Ogawa Y, Nomura K, Sho K, Omura M, Sekiguchi K, Kikuchi Y, Michikawa Y, Noda S, Sagara M, Ohashi J, Yoshinaga S, Mizoe J, Tsujii H, Iwakawa M, Imai T: **Haplotype-based analysis of genes associated with risk of adverse skin reactions after radiotherapy in breast cancer patients.** *International journal of radiation oncology, biology, physics* 2007, **69**:685-693.
  45. Lindsay KJ, Coates PJ, Lorimore SA, Wright EG: **The genetic basis of tissue responses to ionizing radiation.** *The British journal of radiology* 2007, **80**(Spec No 1):S2-6.
  46. De Ruyck K, Van Eijkeren M, Claes K, Morthier R, De Paep A, Vral A, De Ridder L, Thierens H: **Radiation-induced damage to normal tissues after radiotherapy in patients treated for gynecologic tumors: association with single nucleotide polymorphisms in XRCC1, XRCC3, and OGG1 genes and in vitro chromosomal radiosensitivity in lymphocytes.** *International journal of radiation oncology, biology, physics* 2005, **62**:1140-1149.
  47. Mori N, Matsumoto Y, Okumoto M, Suzuki N, Yamate J: **Variations in Prkdc encoding the catalytic subunit of DNA-dependent protein kinase (DNA-PKcs) and susceptibility to radiation-induced apoptosis and lymphomagenesis.** *Oncogene* 2001, **20**:3609-3619.
  48. van Os R, Sheridan TM, Robinson S, Druktein D, Ferrara JL, Mauch PM: **Immunogenicity of Ly5 (CD45)-antigens hampers long-term engraftment following minimal conditioning in a**

**murine bone marrow transplantation model.** *Stem cells (Dayton, Ohio)* 2001, **19**:80-87.

49. Goel HC, Prakash H, Ali A, Bala M: **Podophyllum hexandrum modulates gamma radiation-induced immunosuppression in Balb/c mice: implications in radioprotection.** *Molecular and cellular biochemistry* 2007, **295**:93-103.

Publish with **BioMed Central** and every scientist can read your work free of charge

*"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."*

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:  
[http://www.biomedcentral.com/info/publishing\\_adv.asp](http://www.biomedcentral.com/info/publishing_adv.asp)

